Pulmonx (LUNG) Revenue (2019 - 2025)

Pulmonx (LUNG) has 7 years of Revenue data on file, last reported at $21.5 million in Q3 2025.

• Quarterly Revenue rose 5.47% year-over-year to $21.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $91.7 million (up 15.59% YoY) and the FY2024 annual result came in at $83.8 million, up 22.01% from the prior year.
• Revenue declined to $21.5 million in Q3 2025 per LUNG's latest filing, from $23.9 million in the prior quarter.
• Across five years, Revenue topped out at $23.9 million in Q2 2025 and bottomed at $9.2 million in Q1 2021.
• The 5-year median for Revenue is $17.2 million (2023), against an average of $17.0 million.
• The widest annual swing landed in 2021, when Revenue surged 232.24%; it then climbed 1.82% in 2022.
• Tracing LUNG's Revenue over 5 years: stood at $13.7 million in 2021, then increased by 12.53% to $15.4 million in 2022, then climbed by 24.98% to $19.3 million in 2023, then advanced by 23.28% to $23.8 million in 2024, then retreated by 9.52% to $21.5 million in 2025.
• Per Business Quant, the three latest LUNG Revenue figures stand at $21.5 million (Q3 2025), $23.9 million (Q2 2025), and $22.5 million (Q1 2025).

Peer Comparison